CORCEPT THERAPEUTICS INC (CORT) Form 8-K — Sep 23, 2026
Corcept Therapeutics announced that Sean Maduck, President of its Endocrinology division, will retire effective October 1, 2026, after 14 years helping build the company's Cushing's syndrome franchise. Justin Gunn, who joined Corcept in July 2024 from Gilead Sciences and built the sales organization behind the Lifyorli launch, will succeed Maduck as President of Endocrinology and join the executive team reporting to CEO Joseph Belanoff. Maduck signed a Consulting Services Agreement paying $57,000 per month through September 30, 2027, with his outstanding stock options continuing to vest during the consulting term.
Key figures
- Consulting term end
- 2027-09-30
- Resignation effective
- 2026-10-01
- Consulting fee monthly
- 57000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.